

## AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

### Listing of Claims

1-161. (Canceled)

162. (Previously presented) A compound comprising a peptide chain approximately 12 to 40 amino acids in length that binds to G-CSFR and contains a sequence of amino acids of formula (V) (V)

$CX^{IV}_1X^{IV}_2X^{IV}_3X^{IV}_4X^{IV}_5X^{IV}_6X^{IV}_7X^{IV}_8X^{IV}_9X^{IV}_{10}C$  (SEQ ID NO: 5) wherein each amino acid is indicated by standard one-letter abbreviation, and wherein

$X^{IV}_1$  is E, G, P, N, R, T, W, S, L, H, A, Q or Y;

$X^{IV}_2$  is S, T, E, A, D, G, W, P, L, N, V, Y, R or M;

$X^{IV}_3$  is R, Y, V, Q, E, T, L, P, S, K, M, A or W;

$X^{IV}_4$  is L, M, G, F, W, R, S, V, P, A, D, C or T;

$X^{IV}_5$  is V, T, A, R, S, L, W, C, I, E, P, H, F, D or Q;

$X^{IV}_6$  is E, Y, G, T, Q, M, S, N, A or P;

$X^{IV}_7$  is C, V, D, G, L, W, E, V, I, S, M or A;

$X^{IV}_8$  is S, Y, A, W, P, V, L, Q, G, K, F, I, E or D;

$X^{IV}_9$  is R, W, M, D, H, V, G, A, Q, L, S, E or Y;

$X^{IV}_{10}$  is M, L, I, S, V, P, W, F, T, Y, R, or Q; and wherein said compound does not comprise sequence LLDICELKLQECARRCN (SEQ ID NO: 208).

163. (Previously presented) The compound of claim 162, wherein

$X^{IV}_1$  is E,  $X^{IV}_2$  is S or A,  $X^{IV}_3$  is R,  $X^{IV}_4$  is L,  $X^{IV}_5$  is V or S,  $X^{IV}_6$  is E,  $X^{IV}_7$  is C,  $X^{IV}_8$  is S,  $X^{IV}_9$  is R, and  $X^{IV}_{10}$  is L.

Serial No.: 10/659,207  
Filing Date: September 9, 2003

164. (Previously presented) The compound of claim 162, wherein the sequence of amino acids is selected from the group consisting of:

GGGLLDICELKLQECARRCN (SEQ ID NO: 209);


GRTGGGLLDICELKLQECARRCN (SEQ ID NO: 210);

LGIEGRTGGGLLDICELKLQECARRC- N (SEQ ID NO: 211);

LLDICEELKLQEAARRCN (SEQ ID NO: 212); and

KLLDICELKLQEAARRCN (SEQ ID NO: 213).

165. (Previously presented) The compound of claim 162, comprising a dimer having the structure of formula (VIII)



wherein  $R^1$  and  $R^2$  are independently selected from the sequences of amino acids of formula (V);  $\beta A$  is a  $\beta$ -alanine residue;  $n1$ ,  $n2$ ,  $n3$ ,  $n4$ ,  $x$  and  $y$  are independently zero or one with the proviso that the sum of  $x$  and  $y$  is either one or two; and  $Lk$  is a terminal linking moiety selected from the group consisting of a disulfide bond, a carbonyl moiety, a C1-12 linking moiety optionally terminated with one or two-NH-linkages and optionally substituted at one or more available carbon atoms with a lower alkyl substituent, a lysine residue or a lysine amide.

166. (Previously presented) The compound of claim 162, containing a disulfide bond.

167. (Previously presented) The compound of claims 162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.

169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.

Serial No.: 10/659,207  
Filing Date: September 9, 2003

170. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of any claim 162, in combination with a pharmaceutically acceptable carrier.

171. (Withdrawn) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of claim 162.

172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.

173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.

174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.